Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists
Abstract Aims Data support favourable haemodynamic benefits of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct haemodynamic effects of GLP‐1 RAs remain inadequately characterized...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.15308 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849708713941663744 |
|---|---|
| author | Haoran Jiang Phuuwadith Wattanachayakul Veraprapas Kittipibul Erika Nicolsen Todd McVeigh Oksana Kamneva Marat Fudim |
| author_facet | Haoran Jiang Phuuwadith Wattanachayakul Veraprapas Kittipibul Erika Nicolsen Todd McVeigh Oksana Kamneva Marat Fudim |
| author_sort | Haoran Jiang |
| collection | DOAJ |
| description | Abstract Aims Data support favourable haemodynamic benefits of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct haemodynamic effects of GLP‐1 RAs remain inadequately characterized. We aim to investigate temporal trends of pulmonary artery pressure (PAP) in HF patients receiving GLP‐1 RAs. Methods and results In this single‐centre retrospective cohort study, we identified HF patients with a CardioMEMS device who received semaglutide or tirzepatide for at least 6 months during the monitoring period. Patients who were already on GLP‐1 RAs prior to device implantation were excluded. The relationship between weight change and PAPs was assessed using Pearson correlation. A total of nine patients were included (54 years, BMI 41.4 kg/m2, 67% men, 44% with EF < 40%, 89% diabetes, 89% semaglutide). Median dose of semaglutide (or equivalent) at 6 months was 0.9 (range 0.25–1) mg/week. Body weight significantly decreased from 123.6 to 117.2 kg (P = 0.047), while guideline‐directed medical therapy (GDMT) and loop diuretic uses and dosages remained unchanged. Significant reductions were observed in systolic PAP (38.9 to 34.0 mmHg, P = 0.045), diastolic PAP (20.0 to 17.8 mmHg, P = 0.019) and mean PAP (27.3 to 24.3 mmHg, P = 0.018). There was a significant correlation between weight loss and reductions in systolic PAP (r = 0.69, P = 0.04) and mean PAP (r = 0.72, P = 0.029). Conclusions GLP1‐RA use in HF patients was significantly associated with reductions in body weight and PAPs at 6 months, despite no changes in GDMT and loop diuretic doses. |
| format | Article |
| id | doaj-art-b04a1a920a714e33a185fa50266004ae |
| institution | DOAJ |
| issn | 2055-5822 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj-art-b04a1a920a714e33a185fa50266004ae2025-08-20T03:15:34ZengWileyESC Heart Failure2055-58222025-08-011242578258210.1002/ehf2.15308Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonistsHaoran Jiang0Phuuwadith Wattanachayakul1Veraprapas Kittipibul2Erika Nicolsen3Todd McVeigh4Oksana Kamneva5Marat Fudim6Division of Cardiology Duke University Medical Center Durham North Carolina USADepartment of Medicine Jefferson Einstein Hospital Philadelphia Pennsylvania USADivision of Cardiology Duke University Medical Center Durham North Carolina USADepartment of Pharmacy Duke University Hospital Durham North Carolina USADivision of Cardiology Duke University Medical Center Durham North Carolina USADepartment of Pharmacy Duke University Hospital Durham North Carolina USADivision of Cardiology Duke University Medical Center Durham North Carolina USAAbstract Aims Data support favourable haemodynamic benefits of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on improving cardiac structural abnormalities and function in patients with heart failure (HF). However, the direct haemodynamic effects of GLP‐1 RAs remain inadequately characterized. We aim to investigate temporal trends of pulmonary artery pressure (PAP) in HF patients receiving GLP‐1 RAs. Methods and results In this single‐centre retrospective cohort study, we identified HF patients with a CardioMEMS device who received semaglutide or tirzepatide for at least 6 months during the monitoring period. Patients who were already on GLP‐1 RAs prior to device implantation were excluded. The relationship between weight change and PAPs was assessed using Pearson correlation. A total of nine patients were included (54 years, BMI 41.4 kg/m2, 67% men, 44% with EF < 40%, 89% diabetes, 89% semaglutide). Median dose of semaglutide (or equivalent) at 6 months was 0.9 (range 0.25–1) mg/week. Body weight significantly decreased from 123.6 to 117.2 kg (P = 0.047), while guideline‐directed medical therapy (GDMT) and loop diuretic uses and dosages remained unchanged. Significant reductions were observed in systolic PAP (38.9 to 34.0 mmHg, P = 0.045), diastolic PAP (20.0 to 17.8 mmHg, P = 0.019) and mean PAP (27.3 to 24.3 mmHg, P = 0.018). There was a significant correlation between weight loss and reductions in systolic PAP (r = 0.69, P = 0.04) and mean PAP (r = 0.72, P = 0.029). Conclusions GLP1‐RA use in HF patients was significantly associated with reductions in body weight and PAPs at 6 months, despite no changes in GDMT and loop diuretic doses.https://doi.org/10.1002/ehf2.15308GLP‐1 receptor agonistHeart failurePulmonary artery pressure |
| spellingShingle | Haoran Jiang Phuuwadith Wattanachayakul Veraprapas Kittipibul Erika Nicolsen Todd McVeigh Oksana Kamneva Marat Fudim Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists ESC Heart Failure GLP‐1 receptor agonist Heart failure Pulmonary artery pressure |
| title | Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists |
| title_full | Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists |
| title_fullStr | Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists |
| title_full_unstemmed | Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists |
| title_short | Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists |
| title_sort | pulmonary artery pressure trajectories in heart failure patients treated with glp 1 receptor agonists |
| topic | GLP‐1 receptor agonist Heart failure Pulmonary artery pressure |
| url | https://doi.org/10.1002/ehf2.15308 |
| work_keys_str_mv | AT haoranjiang pulmonaryarterypressuretrajectoriesinheartfailurepatientstreatedwithglp1receptoragonists AT phuuwadithwattanachayakul pulmonaryarterypressuretrajectoriesinheartfailurepatientstreatedwithglp1receptoragonists AT veraprapaskittipibul pulmonaryarterypressuretrajectoriesinheartfailurepatientstreatedwithglp1receptoragonists AT erikanicolsen pulmonaryarterypressuretrajectoriesinheartfailurepatientstreatedwithglp1receptoragonists AT toddmcveigh pulmonaryarterypressuretrajectoriesinheartfailurepatientstreatedwithglp1receptoragonists AT oksanakamneva pulmonaryarterypressuretrajectoriesinheartfailurepatientstreatedwithglp1receptoragonists AT maratfudim pulmonaryarterypressuretrajectoriesinheartfailurepatientstreatedwithglp1receptoragonists |